Replies to post #3627 on Repros Therapeutics Inc (RPRX)

[DewDiligence]

>…but I have NEVER heard a company claim that they were 90% powering for an efficacy of x, because they figure x is the worst efficacy can be and still be sellable.<

I have heard this but it’s not phrased in such crudely commercial language. Management says, “We surveyed 150 of the leading clinicians in this field, asking what magnitude of treatment benefit would induce them to change their treatment regimens to incorporate our drug. They told us __%, and our trials are powered at 90% to show such a benefit.”

[io_io]

<If a trial gets a p value of x (lets go with 0.04), what is the chance that it is an efficacious drug?>

How often does this happen in a Phase 2 ? With any registerable endpoints ??

Perhaps you need to criticise the industry, not for bad Phase 3 design, but for bad Phase 2 design.